Arrowhead Research | ARWR - Selling And Administration Expenses


Arrowhead Research reported $41.74M in Selling and Administration Expenses for its fiscal quarter ending in March of 2026.





Selling And Administration Expenses Change Date
Agios Pharmaceuticals USD 38.46M 4.51M Mar/2026
Alnylam Pharmaceuticals USD 347.92M 65.41M Jun/2026
Anika Therapeutics USD 10.01M 14K Dec/2025
Arrowhead Research USD 41.74M 4.28M Mar/2026
Heron Therapeutics USD 23.74M 605K Dec/2025
Incyte USD 351.73M 23.64M Jun/2026
Ionis Pharmaceuticals USD 130.07M 20.92M Jun/2026
Ligand Pharmaceuticals USD 20.84M 4.19M Mar/2026
Merck USD 2.67B 180M Mar/2026
Moderna USD 216M 43M Jun/2026
Nektar Therapeutics USD 11.87M 1.7M Mar/2026
Novartis USD 3.24B 101M Jun/2026
Sarepta Therapeutics USD 54.03M 51.35M Mar/2026
TG Therapeutics USD 62.32M 10.82M Jun/2026
Ultragenyx Pharmaceutical USD 88M 1000K Mar/2026
Vertex Pharmaceuticals USD 582.2M 88.5M Jun/2026
Xencor USD 82.12M 65.08M Mar/2026